TY - JOUR
T1 - Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer
AU - Escalante, Carmen P.
AU - Rubenstein, Edward B.
AU - Rolston, Kenneth V.I.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1997
Y1 - 1997
N2 - Until recently, febrile neutropenic patients were treated with intravenous antibiotics in inpatient settings. Because of work completed in the last several years by various investigators, identification of a low- risk group of febrile, neutropenic patients has allowed successful treatment with both parenteral and oral antibiotics in an ambulatory environment. This accomplishment has been facilitated by advances in broad-spectrum antibiotics with long half-lives and stabilities, the introduction of the quinolones providing oral antipseudomonal activity, home health care, improvements in vascular access devices, and technically enhanced antibiotic delivery systems. This review focuses on the rationale of risk stratification and the progress made in treating low-risk febrile neutropenic patients as outpatients.
AB - Until recently, febrile neutropenic patients were treated with intravenous antibiotics in inpatient settings. Because of work completed in the last several years by various investigators, identification of a low- risk group of febrile, neutropenic patients has allowed successful treatment with both parenteral and oral antibiotics in an ambulatory environment. This accomplishment has been facilitated by advances in broad-spectrum antibiotics with long half-lives and stabilities, the introduction of the quinolones providing oral antipseudomonal activity, home health care, improvements in vascular access devices, and technically enhanced antibiotic delivery systems. This review focuses on the rationale of risk stratification and the progress made in treating low-risk febrile neutropenic patients as outpatients.
UR - http://www.scopus.com/inward/record.url?scp=0030988533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030988533&partnerID=8YFLogxK
U2 - 10.3109/07357909709039721
DO - 10.3109/07357909709039721
M3 - Review article
C2 - 9171858
AN - SCOPUS:0030988533
SN - 0735-7907
VL - 15
SP - 237
EP - 242
JO - Cancer Investigation
JF - Cancer Investigation
IS - 3
ER -